Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 29Neoplasms 8Neoplasm Metastasis 8Brain Neoplasms 5Prostatic Neoplasms 4Ovarian Neoplasms 4Glioma 4Endometrial Neoplasms 4Triple Negative Breast Neoplasms 3Neoplasms by Site 3Breast Diseases 3Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Meningioma 2Head and Neck Neoplasms 2Glioblastoma 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Spinal Cord Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Kaposi 1Sarcoma, Ewing 1Sarcoma 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1Pathologic Complete Response 1Pancreatic Neoplasms 1Neurofibromatosis 1 1Neoplasms, Squamous Cell 1Neoplasm, Residual 1Multiple Myeloma 1

Interventions

Cyclophosphamide 25fludarabine 19Dexamethasone 17pembrolizumab 13Rituximab 12venetoclax 9Lenalidomide 9Gemcitabine 9Etoposide 9pomalidomide 8Vincristine 7glofitamab 6fludarabine phosphate 6carfilzomib 6Temozolomide 6obinutuzumab 5daratumumab 5Prednisone 5Nivolumab 5Doxorubicin 5Cisplatin 5Calcium Dobesilate 5Bortezomib 5zanubrutinib 4selinexor 4Immunotherapy, Adoptive 4Cytarabine 4Carboplatin 4Azacitidine 4ruxolitinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × abemaciclib × 90 days × Clear all
NCT07209449 2026-05-22

A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
75 enrolled
Gynecologic

Recurrence, Endometrial Neoplasms

NCT06760637 2026-05-19

FourLight-3

Pfizer

Phase 3 Active not recruiting
1,035 enrolled
Breast

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡